Ted Monohon - Feb 1, 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Chief Accounting Officer & VP
Signature
/s/ Ted Monohon
Stock symbol
QNCX
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 05:32 PM
Previous filing
Dec 7, 2022
Next filing
Mar 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Employee Stock Option (right to buy) Award $0 +110K $0.00 110K Feb 1, 2023 Common Stock 110K $0.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.